What are the specific functions and efficacy of Trametinib tablets?

Trametinib is a small molecule inhibitor targeting MEK enzyme (mitogen-activated protein kinase). It is mainly used to treat patients with advanced solid tumors carrying BRAF V600 mutations. It plays an important role in tumors such as malignant melanoma, non-small cell lung cancer (NSCLC) and thyroid cancer. This drug fundamentally blocks the division and proliferation of tumor cells by precisely intervening in cell signaling pathways. It is one of the important representatives of precision medicine.

From the mechanism of action, trametinib can inhibit MEK1 and MEK2, the key nodes in theMAPK/ERK signaling pathway. This pathway is abnormally activated in a variety of tumors due to BRAF gene mutations. By blocking MEK activity, trametinib can effectively reduce the proliferation ability of tumor cells and induce apoptosis, thereby reducing the tumor burden. This targeted effect is different from the "broad-spectrum killing" of traditional chemotherapy, with higher specificity and lower toxic side effects.

The clinical efficacy of trametinib has been verified in multiple international studies. Especially when combined with the BRAF inhibitor dabrafenib, it can form a "dual-targeted attack" on BRAF mutant tumors, delay the emergence of tumor resistance, and significantly improve progression-free survival and overall survival. Based on its excellent performance, this combination regimen has been approved by the US FDA, European EMA and Chinese NMPA, and is recommended as first-line treatment.

In addition, the scope of application of trametinib continues to expand. In recent years, it has shown a strong ability to penetrate the blood-brain barrier in the treatment of patients with brain metastases, providing a new option for advanced patients with limited treatment methods in the past. In terms of research on resistance mechanisms, trametinib is often used as a basic drug to explore more combination strategies, such as its combination with immune checkpoint inhibitors, and has entered a number of international clinical trials.

Reference materials:https://go.drugbank.com/drugs/DB08911